Measuring flu vaccine immunity in COVID-19 patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the immunity response to the flu vaccine over time in individuals aged 13 to 64 who have previously been diagnosed with COVID-19. Participants will include both those with COVID-19 and a control group without the virus, allowing for a comparative analysis of immune responses. The study will focus on patients who may also have other medical conditions such as obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19 symptoms. By monitoring these responses, the study seeks to understand how prior COVID-19 infection influences flu vaccine efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 9 through 64 years
* Diagnosed with COVID-19 at least 2 months prior enrollment
* Patients with or without obesity, diabetes, chronic fatigue and/or long term COVID-19 symptoms
* Patients without COVID-19 diagnosis for controls

Exclusion Criteria:

* Received the influenza vaccine less than 4 months ago
* Pregnant or lactating
* Patients with special risks attendant to venipuncture
* Use of immunomodulatory medications that may impact vaccine immune response per clinician's judgment
* Contraindication to the flu vaccine
* Immunodeficiency or autoimmune disease that may impact vaccine immune responses per clinician's judgement

Where it's running

• Stanford University
  Palo Alto, California, United States Recruiting

Study contacts

• Principal investigator: Sayantani Sindher, MD — Stanford University
• Study coordinator: SNP Center Inquiry
• Email: snpcenterallergy_inquiry@stanford.edu
• Phone: (650) 521-7237

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bacillus coagulans SNZ 1969 for immune health in school-aged children

  This trial will try whether daily Bacillus coagulans SNZ 1969 reduces respiratory and gastrointestinal symptoms and changes immune markers in healthy 6–12-year-old children.

  Recruiting Sanzyme Biologics Private Limited · London, Ontario · NCT07341750

• Bloom Infant Probiotic: Can a probiotic help vaccines work better after early antibiotics?

  We’re testing if giving Infloran probiotic to newborns who had antibiotics in the first 28 days helps their vaccines produce stronger antibodies.

  Recruiting Phase 2 South Australian Health and Medical Research Institute · Adelaide, South Australia and 1 other locations · NCT07189390

• Understanding how long COVID-19 can persist after recovery

  This study is trying to find out how long the COVID-19 virus can stick around in people who have recovered and how quickly their bodies make antibodies.

  Recruiting Columbia University · New York, New York · NCT04448145

• New treatments for COVID-19 using nitazoxanide and ivermectin

  This study is testing if the medications nitazoxanide and ivermectin, alone or with other drugs, can help people with COVID-19 feel better.

  Recruiting at 2 sites Phase 3 Tanta University · Tanta and 1 other locations · NCT04382846

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.